Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine

Galunisertib, a Transforming growth factor-βRI (TGF-βRI) kinase inhibitor, blocks TGF-β-mediated tumor growth in glioblastoma. In a three-arm study of galunisertib (300 mg/day) monotherapy (intermittent dosing; each cycle =14 days on/14 days off), lomustine monotherapy, and galunisertib plus lomusti...

Descripción completa

Detalles Bibliográficos
Autores principales: Capper, David, von Deimling, Andreas, Brandes, Alba A., Carpentier, Antoine F., Kesari, Santosh, Sepulveda-Sanchez, Juan M., Wheeler, Helen R., Chinot, Olivier, Cher, Lawrence, Steinbach, Joachim P., Specenier, Pol, Rodon, Jordi, Cleverly, Ann, Smith, Claire, Gueorguieva, Ivelina, Miles, Colin, Guba, Susan C., Desaiah, Durisala, Estrem, Shawn T., Lahn, Michael M., Wick, Wolfgang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5454908/
https://www.ncbi.nlm.nih.gov/pubmed/28481241
http://dx.doi.org/10.3390/ijms18050995

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5454908/
https://www.ncbi.nlm.nih.gov/pubmed/28481241
http://dx.doi.org/10.3390/ijms18050995

Ejemplares similares